Aclaris’ mixed PhIIb eczema data; Amgen licenses Xeris’ tech; Bolden Tx secures funding

Aclaris Ther­a­peu­tics re­port­ed mixed re­sults for its JAK in­hibitor in a Phase IIb eczema study. The biotech seeks a part­ner for next steps. Aclaris an­nounced Wednes­day that at four weeks, its JAK 1/3 in­hibitor ATI-1777 sig­nif­i­cant­ly re­duced scores from base­line on a mea­sure of eczema sever­i­ty com­pared to place­bo in pa­tients who re­ceived the treat­ment twice dai­ly. How­ev­er, in those who re­ceived the treat­ment once a day, ATI-1777 failed to hit sta­tis­ti­cal sig­nif­i­cance. Aclaris’ shares $ACRS dropped about 25% Wednes­day morn­ing to be­low $1. Aclaris’ share val­ue has fall­en near­ly 95% over the past year af­ter a se­ries of clin­i­cal tri­al fails, and in De­cem­ber, the biotech laid off just un­der half of its staff. — Lei Lei Wu

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.